226 related articles for article (PubMed ID: 25149982)
1. Silymarin liposomes improves oral bioavailability of silybin besides targeting hepatocytes, and immune cells.
Kumar N; Rai A; Reddy ND; Raj PV; Jain P; Deshpande P; Mathew G; Kutty NG; Udupa N; Rao CM
Pharmacol Rep; 2014 Oct; 66(5):788-98. PubMed ID: 25149982
[TBL] [Abstract][Full Text] [Related]
2. Improved in vitro and in vivo hepatoprotective effects of liposomal silymarin in alcohol-induced hepatotoxicity in Wistar rats.
Kumar N; Rai A; Reddy ND; Shenoy RR; Mudgal J; Bansal P; Mudgal PP; Arumugam K; Udupa N; Sharma N; Rao CM
Pharmacol Rep; 2019 Aug; 71(4):703-712. PubMed ID: 31207432
[TBL] [Abstract][Full Text] [Related]
3. Effects of silymarin nanoemulsion against carbon tetrachloride-induced hepatic damage.
Parveen R; Baboota S; Ali J; Ahuja A; Vasudev SS; Ahmad S
Arch Pharm Res; 2011 May; 34(5):767-74. PubMed ID: 21656362
[TBL] [Abstract][Full Text] [Related]
4. Oil based nanocarrier for improved oral delivery of silymarin: In vitro and in vivo studies.
Parveen R; Baboota S; Ali J; Ahuja A; Vasudev SS; Ahmad S
Int J Pharm; 2011 Jul; 413(1-2):245-53. PubMed ID: 21549187
[TBL] [Abstract][Full Text] [Related]
5. A New Type of Liquid Silymarin Proliposome Containing Bile Salts: Its Preparation and Improved Hepatoprotective Effects.
Wang M; Xie T; Chang Z; Wang L; Xie X; Kou Y; Xu H; Gao X
PLoS One; 2015; 10(12):e0143625. PubMed ID: 26674103
[TBL] [Abstract][Full Text] [Related]
6. Phytosome-nanosuspensions for silybin-phospholipid complex with increased bioavailability and hepatoprotection efficacy.
Chi C; Zhang C; Liu Y; Nie H; Zhou J; Ding Y
Eur J Pharm Sci; 2020 Mar; 144():105212. PubMed ID: 31923602
[TBL] [Abstract][Full Text] [Related]
7. Silymarin-loaded solid nanoparticles provide excellent hepatic protection: physicochemical characterization and in vivo evaluation.
Yang KY; Hwang du H; Yousaf AM; Kim DW; Shin YJ; Bae ON; Kim YI; Kim JO; Yong CS; Choi HG
Int J Nanomedicine; 2013; 8():3333-43. PubMed ID: 24039417
[TBL] [Abstract][Full Text] [Related]
8. Preparation of silymarin proliposome: a new way to increase oral bioavailability of silymarin in beagle dogs.
Yan-yu X; Yun-mei S; Zhi-peng C; Qi-neng P
Int J Pharm; 2006 Aug; 319(1-2):162-8. PubMed ID: 16687221
[TBL] [Abstract][Full Text] [Related]
9. Preparation and pharmacological evaluation of silibinin liposomes.
Maheshwari H; Agarwal R; Patil C; Katare OP
Arzneimittelforschung; 2003; 53(6):420-7. PubMed ID: 12872613
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of the in-vitro dissolution and in-vivo oral bioavailability of silymarin from liquid-filled hard gelatin capsules of semisolid dispersion using Gelucire 44/14 as a carrier.
Hussein A; El-Menshawe S; Afouna M
Pharmazie; 2012 Mar; 67(3):209-14. PubMed ID: 22530301
[TBL] [Abstract][Full Text] [Related]
11. Formulation and biopharmaceutical evaluation of supersaturatable self-nanoemulsifying drug delivery systems containing silymarin.
Tung NT; Tran CS; Nguyen HA; Nguyen TD; Chi SC; Pham DV; Bui QD; Ho XH
Int J Pharm; 2019 Jan; 555():63-76. PubMed ID: 30448315
[TBL] [Abstract][Full Text] [Related]
12. Comparative study of different silymarin formulations: formulation, characterisation and in vitro/in vivo evaluation.
Abrol S; Trehan A; Katare OP
Curr Drug Deliv; 2005 Jan; 2(1):45-51. PubMed ID: 16305407
[TBL] [Abstract][Full Text] [Related]
13. Reassessing bioavailability of silymarin.
Javed S; Kohli K; Ali M
Altern Med Rev; 2011 Sep; 16(3):239-49. PubMed ID: 21951025
[TBL] [Abstract][Full Text] [Related]
14. Silymarin loaded liposomes for hepatic targeting: in vitro evaluation and HepG2 drug uptake.
Elmowafy M; Viitala T; Ibrahim HM; Abu-Elyazid SK; Samy A; Kassem A; Yliperttula M
Eur J Pharm Sci; 2013 Oct; 50(2):161-71. PubMed ID: 23851081
[TBL] [Abstract][Full Text] [Related]
15. Chitosan-functionalized lipid-polymer hybrid nanoparticles for oral delivery of silymarin and enhanced lipid-lowering effect in NAFLD.
Liang J; Liu Y; Liu J; Li Z; Fan Q; Jiang Z; Yan F; Wang Z; Huang P; Feng N
J Nanobiotechnology; 2018 Sep; 16(1):64. PubMed ID: 30176941
[TBL] [Abstract][Full Text] [Related]
16. Proliposomes for oral delivery of dehydrosilymarin: preparation and evaluation in vitro and in vivo.
Chu C; Tong SS; Xu Y; Wang L; Fu M; Ge YR; Yu JN; Xu XM
Acta Pharmacol Sin; 2011 Jul; 32(7):973-80. PubMed ID: 21666703
[TBL] [Abstract][Full Text] [Related]
17. Enhanced Bioavailability and Efficacy of Silymarin Solid Dispersion in Rats with Acetaminophen-Induced Hepatotoxicity.
Song IS; Nam SJ; Jeon JH; Park SJ; Choi MK
Pharmaceutics; 2021 Apr; 13(5):. PubMed ID: 33925040
[TBL] [Abstract][Full Text] [Related]
18. Mesoporous silica nanoparticles, a safe option for silymarin delivery: preparation, characterization, and in vivo evaluation.
Nasr SS; Nasra MMA; Hazzah HA; Abdallah OY
Drug Deliv Transl Res; 2019 Oct; 9(5):968-979. PubMed ID: 31001719
[TBL] [Abstract][Full Text] [Related]
19. Enhanced bioavailability and hepatoprotectivity of optimized ursolic acid-phospholipid complex.
Biswas S; Mukherjee PK; Harwansh RK; Bannerjee S; Bhattacharjee P
Drug Dev Ind Pharm; 2019 Jun; 45(6):946-958. PubMed ID: 30767678
[TBL] [Abstract][Full Text] [Related]
20. Potential protective effect of honey against paracetamol-induced hepatotoxicity.
Galal RM; Zaki HF; Seif El-Nasr MM; Agha AM
Arch Iran Med; 2012 Nov; 15(11):674-80. PubMed ID: 23102243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
